Recombinant Interleukin-1 Receptor Antagonist Conjugated to Superparamagnetic Iron Oxide Nanoparticles for Theranostic Targeting of Experimental Glioblastoma

Neoplasia (United States)

Volumn 17, Issue 1, 2015, Pages 32-42

  Shevtsov, Maxim A ^a,b   Nikolaev, Boris P ^c   Yakovleva, Ludmila Y ^c   Dobrodumov, Anatolii V ^d   Zhakhov, Alexander V ^c   Mikhrina, Anastasiy L ^e   Pitkin, Emil ^f   Parr, Marina A ^g   Rolich, Valerii I ^g   Simbircev, Andrei S ^c   Ischenko, Alexander M ^c  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^c Institute for Highly Pure Biopreparations   (Russian Federation)

^d INSTITUTE OF MACROMOLECULAR COMPOUNDS   (Russian Federation)

^e SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; INTERLEUKIN 1 RECEPTOR; MAGNETITE NANOPARTICLE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EDEMA; BRAIN TUMOR; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; GLIOBLASTOMA; IN VITRO STUDY; LIFESPAN; LYMPHOCYTE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RAT; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CHEMISTRY; EXPERIMENTAL NEOPLASM; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; FERRIC COMPOUNDS; GLIOBLASTOMA; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; NEOPLASMS, EXPERIMENTAL; RATS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS;

EID: 84964693292     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.11.001     Document Type: Article

References (49)

1. [1] Schoenegger, K., Oberndorfer, S., Wuschitz, B., Struhal, W., Hainfellner, J., Prayer, D., Heinzl, H., Lahrmann, H., Marosi, C., Grisold, W., Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?. Eur J Neurol 16 (2009), 874–878.
2. [2] Koehler, P.J., Use of corticosteroids in neuro-oncology. Anticancer Drugs 16 (1995), 19–33.
3. [3] Dietrich, J., Rao, K., Pastorino, S., Kesari, S., Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 4 (2011), 233–242.
4. [4] Roth, P., Regli, L., Tonder, M., Weller, M., Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther 13 (2013), 1319–1325.
5. [5] Badie, B., Schartner, J.M., Hagar, A.R., Prabakaran, S., Peebles, T.R., Bartley, B., Lapsiwala, S., Resnick, D.K., Vorpahl, J., Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res 9 (2003), 872–877.
6. [6] Rinne, M.L., Lee, E.Q., Nayak, L., Norden, A.D., Beroukhim, R., Wen, P.Y., Reardon, D.A., Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 18 (2013), 137–153.
7. [7] Zhang, X., Cong, D., Shen, D., Gao, X., Chen, L., Hu, S., The effect of bumetanide on photodynamic therapy-induced peri-tumor edema of C6 glioma xenografts. Lasers Surg Med 46 (2014), 422–430.
8. [8] Grände, P.O., Romner, B., Osmotherapy in brain edema: a questionable therapy. J Neurosurg Anesthesiol 24 (2012), 407–412.
9. [9] Masada, T., Hua, Y., Xi, G., Yang, G.Y., Hoff, J.T., Keep, R.F., Nagao, S., Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin. Acta Neurochir Suppl 86 (2003), 463–467.
10. [10] Masada, T., Hua, Y., Xi, G., Yang, G.Y., Hoff, J.T., Keep, R.F., Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist. J Neurosurg 95 (2001), 680–686.
11. [11] Tehranian, R., Andell-Jonsson, S., Beni, S.M., Yatsiv, I., Shohami, E., Bartfai, T., Lundkvist, J., Iverfeldt, K., Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 19 (2002), 939–951.
12. [12] Girard, S., Sébire, H., Brochu, M.E., Briota, S., Sarret, P., Sébire, G., Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or hypoxic-ischemic injuries. Brain Behav Immun 26 (2012), 1331–1339.
13. [13] Pradillo, J.M., Denes, A., Greenhalgh, A.D., Boutin, H., Drake, C., McColl, B.W., Barton, E., Proctor, S.D., Russell, J.C., Rothwell, N.J., et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 32 (2012), 1810–1819.
14. [14] Bar, D., Apte, R.N., Voronov, E., Dinarello, C.A., Cohen, S., A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 18 (2004), 161–163.
15. [15] Elaraj, D.M., Weinreich, D.M., Varghese, S., Puhlman, M., Hewitt, S.M., Carroll, N.M., Feldman, E.D., Turner, E.M., Alexander, H.R., The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12 (2006), 1088–1096.
16. [16] Weinreich, D.M., Elaraj, D.M., Puhlmann, M., Hewitt, S.M., Carroll, N.M., Feldman, E.D., Turner, E.M., Spiess, P.J., Alexander, H.R., Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res 63 (2003), 5957–5961.
17. [17] Fuchigami, T., Kibe, T., Koyama, H., Kishida, S., Iijima, M., Nishizawa, Y., Hijioka, H., Fujii, T., Ueda, M., Nakamura, N., et al. Regulation of IL-6 and IL-8 production by reciprocal cell-to-cell interactions between tumor cells and stromal fibroblasts through IL-1α in ameloblastoma. Biochem Biophys Res Commun 451 (2014), 491–496.
18. [18] Greenhalgh, A.D., Galea, J., Dénes, A., Tyrrell, P.J., Rothwell, N.J., Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol 160 (2010), 153–159.
19. [19] Shevtsov, M.A., Yakovleva, L.Y., Nikolaev, B.P., Marchenko, Y.Y., Dobrodumov, A.V., Onokhin, K.V., Onokhina, Y.S., Selkov, S.A., Mikhrina, A.L., Guzhova, I.V., et al. Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma. Neuro Oncol 16 (2014), 38–49.
20. [20] Marchenko, Y.Y., Shishkin, A.N., Yakovleva, L.Y., Nikolaev, B.P., The magnetic relaxation platform for biosensing cancer markers: the relaxivity of magnetic nanoparticles conjugated with epidermal growth factor under influence of its antibody. NMRCM 2012, 9th meeting: “NMR in Heterogeneous Systems”, St. Petersburg, Russia, July 9–13, 2012, 104 [Book of abstracts].
21. [21] Shevtsov, M.A., Nikolaev, B.P., Yakovleva, L.Y., Marchenko, Y.Y., Dobrodumov, A.V., Mikhrina, A.L., Martynova, M.G., Bystrova, O.A., Yakovenko, I.V., Ischenko, A.M., Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine 9 (2014), 273–287.
22. [22] Fuss, I.J., Kanof, M.E., Smith, P.D., Zola, H., Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol, 2009, 10.1002/0471142735.im0701s85.
23. [23] Li, M., Deng, H., Peng, H., Wang, Q., Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol 14 (2014), 415–432.
24. [24] Tzeng, S.Y., Green, J.J., Therapeutic nanomedicine for brain cancer. Ther Deliv 4 (2013), 687–704.
25. [25] Urries, I., Muñoz, C., Gomez, L., Marquina, C., Sebastian, V., Arruebo, M., Santamaria, J., Magneto-plasmonic nanoparticles as theranostic platforms for magnetic resonance imaging, drug delivery and NIR hyperthermia applications. Nanoscale 6 (2014), 9230–9240.
26. [26] Wang, B., Lu, L., Wang, Z., Zhao, Y., Wu, L., Fang, X., Xu, Q., Xin, H., Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis. Biomaterials 35 (2014), 5897–5907.
27. [27] Hadjipanayis, C.G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A.J., Chen, H., Wu, X., Mao, H., EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 70 (2010), 6303–6312.
28. [28] Hu, Q., Gu, G., Liu, Z., Jiang, M., Kang, T., Miao, D., Tu, Y., Pang, Z., Song, Q., Yao, L., et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials 34 (2013), 1135–1145.
29. [29] Apte, R.N., Dotan, S., Elkabets, M., White, M.R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., Voronov, E., The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2 (2006), 387–408.
30. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J Immunol 175 (2005), 8200–8208.
31. [31] Bunt, S.K., Sinha, P., Clements, V.K., Leips, J., Ostrand-Rosenberg, S., Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176 (2006), 284–290.
32. 18F]-IL1RA and PET imaging in rats. Br J Pharmacol 162 (2011), 659–672.
33. [33] Leten, C., Struys, T., Dresselaers, T., Himmelreich, U., In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J Neurooncol 119 (2014), 297–306.
34. [34] Watkins, S., Robel, S., Kimbrough, I.F., Robert, S.M., Ellis-Davies, G., Sontheimer, H., Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun, 5, 2014, 4196.
35. [35] Huang, Y., Hoffman, C., Rajappa, P., Kim, J.H., Hu, W., Huse, J., Tang, Z., Li, X., Weksler, B., Bromberg, J., et al. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 74 (2014), 1011–1021.
36. [36] Nduom, E.K., Yang, C., Merrill, M.J., Zhuang, Z., Lonser, R.R., Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg 119 (2013), 427–433.
37. [37] Nowosielski, M., Recheis, W., Goebel, G., Güler, O., Tinkhauser, G., Kostron, H., Schocke, M., Gotwald, T., Stockhammer, G., Hutterer, M., ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53 (2011), 291–302.
38. [38] Hawkins-Daarud, A., Rockne, R.C., Anderson, A.R., Swanson, K.R., Modeling tumor-associated edema in gliomas during anti-angiogenic therapy and its impact on imageable tumor. Front Oncol, 3, 2013, 66.
39. [39] Yang, L.J., Lin, Z.X., Kang, D.Z., Weng, S.M., Lin, J.H., Huang, Q., Zhang, P.F., Effects of endostatin on C6 glioma-induced edema. Chin Med J (Engl) 124 (2011), 4211–4216.
40. [40] Dietrich, J., Wang, D., Batchelor, T.T., Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 18 (2009), 1549–1557.
41. [41] McKenzie, R.C., Oran, A., Dinarello, C.A., Sauder, D.N., Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Res 16 (1996), 437–441.
42. [42] Lavi, G., Voronov, E., Dinarello, C.A., Apte, R.N., Cohen, S., Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 123 (2007), 123–130.
43. [43] Triozzi, P.L., Aldrich, W., Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res 30 (2010), 345–354.
44. [44] Triozzi, P.L., Aldrich, W., Singh, A., Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci 52 (2011), 5529–5535.
45. [45] Li, K., Shen, M., Zheng, L., Zhao, J., Quan, Q., Shi, X., Zhang, G., Magnetic resonance imaging of glioma with novel APTS-coated superparamagnetic iron oxide nanoparticles. Nanoscale Res Lett, 9, 2014, 304.
46. [46] Cui, Y., Xu, Q., Chow, P.K., Wang, D., Wang, C.H., Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 34 (2013), 8511–8520.
47. [47] Singh, V., Nair, S.P., Aradhyam, G.K., Chemistry of conjugation to gold nanoparticles affects G-protein activity differently. J Nanobiotechnology, 11, 2013, 7.
48. [48] Saptarshi, S.R., Duschl, A., Lopata, A.L., Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnology, 11, 2013, 26.
49. [49] Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73 (2013), 2412–2417.